Results 31 to 40 of about 222,830 (234)

Automated segmentation of left ventricular myocardium using cascading convolutional neural networks based on echocardiography

AIP Advances, 2021
Quickly and accurately segmenting the left ventricular (LV) myocardium from ultrasound images and measuring the thickness of the interventricular septum and LV wall play an important role in hypertrophic cardiomyopathy.
Shenghan Ren, Yongbing Wang, Rui Hu, Lei Zuo, Liwen Liu, Heng Zhao   +5 more
doaj   +1 more source

Hypertrophic cardiomyopathy: the future of treatment

European Journal of Heart Failure, 2020
Hypertrophic cardiomyopathy (HCM) is a heterogeneous genetic disorder most often caused by sarcomeric mutations resulting in left ventricular hypertrophy, fibrosis, hypercontractility, and reduced compliance.
C. V. Tuohy, S. Kaul, Howard K Song, B. Nazer, S. Heitner   +4 more
semanticscholar   +1 more source

Subcutaneous Implantable Cardioverter Defibrillator in Patients With Hypertrophic Cardiomyopathy: An Initial Experience

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2016
BackgroundThe subcutaneous implantable cardioverter defibrillator (S‐ICD) has been developed to avert risks associated with transvenous defibrillator leads. The technology is attractive for younger patients, such as those with hypertrophic cardiomyopathy
Jonathan Weinstock, Yousef H. Bader, Martin S. Maron, Ethan J. Rowin, Mark S. Link   +4 more
doaj   +1 more source

Probing Subcellular Nanostructure of Engineered Human Cardiomyocytes in 3D Tissue [PDF]

, 2021
The structural and functional maturation of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) is essential for application to pharmaceutical testing, disease modeling, and ultimately therapeutic use. Multicellular 3D-tissue platforms have improved functional maturation of hiPSC-CMs, but probing cardiac contractile properties ...
arxiv   +1 more source

Syndrome of Reversible Cardiogenic Shock and Left Ventricular Ballooning in Obstructive Hypertrophic Cardiomyopathy

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background Cardiogenic shock from most causes has unfavorable prognosis. Hypertrophic cardiomyopathy (HCM) can uncommonly present with apical ballooning and shock in association with sudden development of severe and unrelenting left ventricular (LV ...
Mark V. Sherrid, Daniel G. Swistel, Iacopo Olivotto, Maurizio Pieroni, Omar Wever‐Pinzon, Katherine Riedy, Richard G. Bach, Mustafa Husaini, Sharon Cresci, Alex Reyentovich, Daniele Massera, Martin S. Maron, Barry J. Maron, Bette Kim   +13 more
doaj   +1 more source

Hypertrophic cardiomyopathy in athletes [PDF]

European Cardiology Review, 2017
The diagnosis of hypertrophic cardiomyopathy can be challenging in the athlete. A morphologically mild phenotype of the condition may mimic physiological left ventricular hypertrophy and requires careful evaluation of the athlete with an array of clinical tools.
Malhotra, Aneil, Sharma, Sanjay
openaire   +3 more sources

Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy.

Circulation Research, 2017
Hypertrophic cardiomyopathy (HCM) is a genetic disorder that is characterized by left ventricular hypertrophy unexplained by secondary causes and a nondilated left ventricle with preserved or increased ejection fraction.
A. Marian, E. Braunwald
semanticscholar   +1 more source

Apical Hypertrophic Cardiomyopathy: The Variant Less Known

Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease, 2020
H ypertrophic cardiomyopathy (HCM) is an umbrella term for a heterogeneous heart muscle disease that was historically (and still is) defined by the detection of left ventricular (LV) hypertrophy (LVH) in the absence of abnormal cardiac loading conditions.
R. Hughes, K. Knott, J. Malcolmson, J. Augusto, Saidi A Mohiddin, P. Kellman, J. Moon, G. Captur   +7 more
semanticscholar   +1 more source

Cardiomyocyte-targeted and 17β-estradiol-loaded acoustic nanoprobes as a theranostic platform for cardiac hypertrophy

Journal of Nanobiotechnology, 2018
Background Theranostic perfluorocarbon nanoprobes have recently attracted attention due to their fascinating versatility in integrating diagnostics and therapeutics into a single system.
Xueli Zhao, Wen Luo, Jing Hu, Lei Zuo, Jing Wang, Rui Hu, Bo Wang, Lei Xu, Jing Li, Meng Wu, Pan Li, Liwen Liu   +11 more
doaj   +1 more source

Spatial and Functional Distribution of MYBPC3 Pathogenic Variants and Clinical Outcomes in Patients With Hypertrophic Cardiomyopathy

Circulation Genomic and Precision Medicine, 2020
Supplemental Digital Content is available in the text. Background: Pathogenic variants in MYBPC3, encoding cardiac MyBP-C (myosin binding protein C), are the most common cause of familial hypertrophic cardiomyopathy.
A. Helms, A. Thompson, Amelia A. Glazier, Neha Hafeez, Samat Kabani, Juliani Rodriguez, Jaime Yob, H. Woolcock, F. Mazzarotto, N. Lakdawala, S. Wittekind, A. Pereira, D. Jacoby, S. Colan, E. Ashley, S. Saberi, J. Ware, J. Ingles, C. Semsarian, M. Michels, I. Olivotto, Carolyn Y. Ho, S. Day   +22 more
semanticscholar   +1 more source